Prognostic value of platelet derived growth factor α receptor expression in grade 2 astrocytomas and oligoastrocytomas

被引:20
作者
Ribom, D [1 ]
Andræ, J
Frielingsdorf, M
Hartman, M
Nistér, M
Smits, A
机构
[1] Univ Hosp, Dept Neurosci, SE-75185 Uppsala, Sweden
[2] Univ Hosp, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden
关键词
D O I
10.1136/jnnp.72.6.782
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To determine whether the expression of platelet derived growth factor a receptor (PDGFRalpha) in low grade astrocytomas and oligoastrocytomas is associated with survival. Methods: Formalin fixed and paraffin embedded tumour samples of 40 consecutive patients with supratentorial diffuse astrocytomas and oligoastrocytomas of WHO grade 2, resected between 1986 and 1993, were used for immunohistochemical staining. The fraction of tumour cells expressing PDGFRalpha protein was quantified and entered into univariate and multivariate survival analyses. Changes in PDGFalpha expression over time were analysed in seven patients in whom reoperations had been performed. Results: Patients with a relatively high fraction of PDGFRalpha expressing cells had a more favourable outcome in both univariate (p = 0.04) and multivariate analyses (p = 0.02). Expression of PDGFRalpha was greater in oligoastrocytomas than in astrocytomas (p = 0.05). In four reoperated patients with histologically confirmed malignant transformation, there was a marked decrease in the number of cells expressing the receptor. Conclusions: There is an association between high PDGFRalpha expression and long survival time in patients with grade 2 astrocytomas and oligoastrocytomas. The findings suggest that expression of the receptor may be a useful prognostic marker in such patients.
引用
收藏
页码:782 / 787
页数:6
相关论文
共 32 条
[11]  
GILBERTSON DG, 2001, J BIOL CHEM, V10, P10
[12]  
HART IK, 1989, DEVELOPMENT, V105, P595
[13]   PLATELET-DERIVED GROWTH-FACTOR - MECHANISM OF ACTION AND POSSIBLE INVIVO FUNCTION [J].
HELDIN, CH ;
WESTERMARK, B .
CELL REGULATION, 1990, 1 (08) :555-566
[14]  
HERMANSON M, 1992, CANCER RES, V52, P3213
[15]  
Hermanson M, 1996, CANCER RES, V56, P164
[16]   A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European organization for research and treatment of cancer (EORTC) study 22844 [J].
Karim, ABMF ;
Maat, B ;
Hatlevoll, R ;
Menten, J ;
Rutten, EHJM ;
Thomas, DGT ;
Mascarenhas, F ;
Horiot, JC ;
Parvinen, LM ;
vanReijn, M ;
Hamers, HP ;
Gaspar, L ;
Noordman, E ;
Pierart, M ;
vanGlabbeke, M ;
vanAlphen, AM ;
Jager, JJ ;
Fabrini, MG .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 36 (03) :549-556
[17]   Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer study 22845 with the Medical Research Council study BRO4: An interim analysis [J].
Karim, ABMF ;
Afra, D ;
Cornu, P ;
Bleehan, N ;
Schraub, S ;
De Witte, O ;
Darcel, F ;
Stenning, S ;
Pierart, M ;
Van Glabbeke, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (02) :316-324
[18]  
KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO
[19]  
2-L
[20]   Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: Results of a randomised phase III trial on dose response (EORTC trial 22844) [J].
Kiebert, GM ;
Curran, D ;
Aaronson, NK ;
Bolla, M ;
Menten, J ;
Rutten, EHJM ;
Nordman, E ;
Silvestre, ME ;
Pierart, M ;
Karim, ABMF .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (12) :1902-1909